Clinical Trial · NCT04114370

Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma

Overview

This is a pilot study to assess the ability of \[F-18\]fluciclovine to differentiate pseudoprogression from progression in participants after therapy, at imaging time points within the 12 week interval post chemoradiation. \[F-18\]fluciclovine. PET will be obtained at the time point in the 12 week interval in which MRI demonstrates increase in enhancing volume with the differential diagnosis of pseudoprogression versus tumor progression. At the same time point (at least 6 hours after \[F-18\]fluciclovine or up to 3 days) F-18 FDG will also be performed consistent with standard clinical practice. The verification of pseudoprogression versus tumor progression will be determined by the regression of enhancing lesion on subsequent MRI imaging obtained as part of standard care.

Sponsor

University of Virginia

Phase

Early Phase 1

Contacts

James M Mountz, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT04114370

Drug / Compound

fluciclovine

Isotope(s):

Target(s):

Amino Acid Transport

Ligand Class: Small Molecules

Eligibility

Inclusion

Inclusion criteria not yet provided.

Exclusion

1\. Are a pregnant or breastfeeding female. 2\. Are participating in a clinical trial of another unlicensed product. 3\. Are undergoing 18F-fluciclovine PET for reason(s) other than newly diagnosed or recurrent glioma. 4\. Have a hypersensitivity to 18F-fluciclovine. 5\. Have acute renal failure or moderate/severe renal impairment, according to local clinical guidelines. 6\. Have a non-MRI compatible implantable device or another contraindication for MRI scan. 7\. Are deemed ineligible to participate for other reasons by an investigator.